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localization for CTGF, TGF-β, and 
type I procollagen-α1, as well as 
CTGF’s effects on TGF-β signaling. 
Using samples of young (21–30 years 
of age) and aged (80 or more years 
of age) but otherwise normal human 
skin, and laser-capture microdissect-
ed cells, the authors show that TGF-β 
and CTGF are normally expressed and 
produced in skin and skin fibroblasts. 
Comparing samples from young and 
aged subjects, Quan et al. found that 
in aged skin and fibroblasts, TGF-β, 
CTGF, and type I procollagen mRNA 
and protein levels were coordinately 
reduced. Using transfected normal 
human dermal fibroblasts, knock-
down of CTGF was associated with 
decreased type I procollagen promoter 
activity (COL1A2), mRNA, and pro-
tein content, whereas overexpression 
of V5-tagged human CTGF increased 
the same readouts. Three approaches 
to block signaling due to endogenous 
TGF-β were used to assess molecular 
mechanisms by which CTGF modu-
lates type I procollagen: (i) a specific 
TGF-βRI kinase inhibitor SB431542, 
(ii) Smad4 knockdown, and (iii) over-
expression of inhibitory Smad7. All 
approaches completely blocked the 
CTGF-mediated increase in type I pro-
collagen expression and production, 
indicating that TGF-β receptor and 
Smad signaling are required. However, 
no effects of CTGF knockdown or over-
expression were observed on TGF-β-
dependent Smad2/3 phosphorylation 
or Smad3 transcriptional activity.
On the basis of these findings, the 
authors conclude that endogenous 
production of both TGF-β and CTGF 
in human dermal fibroblasts normally 
acts to modulate type I procollagen 
expression in skin. They propose that 
this involves a TGF-β/Smad/CTGF 
axis that is operated by interdepen-
dent, yet distinct, mechanisms to 
regulate type I procollagen produc-
tion. Decreased expression of TGF-β 
and CTGF by aged skin fibroblasts is 
proposed to underlie age-associated 
downregulation of the TGF-β/Smad/
CTGF axis, thereby leading to reduced 
type I procollagen expression. These 
results suggest beneficial effects of 
CTGF and provide novel insight into 
the mechanisms of skin aging.
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Could Aging Human skin Use a 
Connective Tissue Growth Factor 
Boost to Increase Collagen Content?
Noelynn Oliver1, Mark Sternlicht1, Karin Gerritsen2  
and Roel Goldschmeding1,2
The roles of connective tissue growth factor (CTGF) and transforming growth 
factor-β (TGF-β), both well-known collagen production stimulators, were 
examined in skin aging. Aged skin and fibroblasts exhibited a coordinate 
decrease in CTGF, TGF-β, and type I procollagen expression and content. CTGF 
knockdown and TGF-β blockade in normal dermal fibroblasts reduced procol-
lagen expression, whereas overexpressing CTGF increased procollagen by a 
TGF-β/smad signaling–dependent mechanism without involving smad2/3.
Journal of Investigative Dermatology (2010) 130, 338–341. doi:10.1038/jid.2009.331
Background
Type I collagen is a major struc-
tural protein in human skin and, by 
mass, the most abundant protein in 
the human body. The association of 
age-dependent collagen loss with 
thinning and fragility of elderly skin 
has long been appreciated, yet the 
underlying mechanisms are not well 
understood. A recent study (Quan 
et al., 2010, this issue) suggests that 
diminished expression of connective 
tissue growth factor (CTGF), together 
with diminished transforming growth 
factor (TGF)-β/Smad signaling, is 
responsible for this progressive loss of 
dermal collagen. CTGF is a secreted, 
matri cellular protein, and, like that 
of other such proteins, its function is 
thought to be regulatory, not struc-
tural. CTGF is generally considered a 
pathogenic factor because of its many 
reported disease associations (Leask 
et al., 2009; Cicha et al., 2009), 
potential macromolecular interac-
tions, and complex gene regulation 
that also involves disease-associated 
processes and factors (Figure 1). The 
evolution of a purely pathogenic fac-
tor is unlikely without invoking an 
extreme selfish-gene concept, and the 
results of Quan et al., which address 
CTGF function in normal young and 
aging skin, provide an alternative 
view of CTGF’s physiological signifi-
cance in tissue homeostasis.
ctGF in aging skin: new findings
By means of associative and mecha-
nistic in vivo and in vitro studies, 
Quan et al. (2010) probe the impor-
tance of CTGF and TGF-β for col-
lagen loss in aging skin. They report 
findings on expression, content, and 
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complexity of ctGF action: binding 
partners, metabolism, and expression
CTGF is a modular protein composed 
of four domains that have homol-
ogy with certain protein motifs. Each 
CTGF domain has been reported to 
interact with biologically active fac-
tors and binding partners to regulate 
their effects (Figure 2). Of note, in 
lung epithelial cells CTGF has been 
reported to enhance binding of TGF-β 
with TGF-β receptor complex, there-
by increasing Smad2 phosphorylation 
and Smad-dependent gene transcrip-
tion (Abreu et al., 2002). However, 
Quan et al. (2010) demonstrate that, 
although CTGF knockdown or over-
expression affected type I procolla-
gen expression in a TGF-β-dependent 
manner, it did not alter Smad2/3 
phosphorylation and had no effect 
on TGF-β/Smad3-dependent reporter 
gene transcription. This observation 
is concordant with an independent 
observation (Pannu et al., 2007) that 
TGF-β-dependent type 1 pro collagen 
production is mediated by Alk1/
Smad1 and ERK1/2, but not Smad 2/3, 
in normal dermal fibroblasts. Together, 
these data do not support a simple 
model of CTGF regulating type I pro-
collagen expression through direct 
augmentation of the TGF-β/Smad2/3 
pathway and are consistent with the 
idea that different mechanisms oper-
ate in human dermal fibroblasts and 
lung epithelial cells. The CTGF–
vascular endothelial growth factor 
(VEGF) relationship and its impact 
on angiogenesis further exemplify 
the potential complexity and con-
text dependence of CTGF action. In 
this case, over and above all the pos-
sible physical interactions, CTGF and 
VEGF can each induce expression of 
the other. Cicha and Goppelt-Struebe, 
(2009) give an excellent review of 
CTGF and angiogenesis, detailing 
evidence for pro-, anti-, and neutral 
effects of CTGF and emphasizing 
that microenvironment strongly influ-
ences outcome. Because translation 
of in vitro findings to whole-organism 
physiology has limitations, bet-
ter insight into context dependence 
of CTGF–VEGF relationships might 
be provided by evaluation of CTGF 
in clinical studies of therapeutics 
Figure 1. CTGF gene regulation is complex. The human connective tissue growth factor (CTGF) 
promoter contains multiple control elements that are regulated by a variety of inducing factors (green 
arrows), inhibitory factors (red dashed lines), and mechanical forces or hypoxic stimuli. Many of these 
regulators are disease associated. CTGF gene transcription is strongly induced by transforming growth 
factor-β (TGF-β) and also by angiotensin II, endothelin-1, and advanced glycation end products, at 
least partially through TGF-β and SMAD-independent pathways. Posttranscriptional control elements 
(CAESAR, cis-acting element of structure-anchored repression) and a functional, scleroderma-associated 
polymorphism (Sp1/Sp3 site) have also been observed. BCE, basal control element; E1–E5, exons 1–5; 
HRE, hypoxia-responsive element; NF-κB, nuclear factor kappa light-chain enhancer of activated B cells; 
TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.
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relationship of ctGF’s physiologic  
and pathogenic functions
The relationship of CTGF’s patho-
physiologic actions to its normal 
physiological functions is unknown; 
therefore, a better understanding of 
CTGF’s biological significance for 
normal and aging skin will be gained 
by collecting mechanistic informa-
tion on both activities. CTGF is essen-
tial in embryonic development, in 
which it is important for normal car-
tilage and bone formation. In adults, 
however, normal physiologic CTGF 
levels appear dispensable because 
animal studies testing CTGF block-
ade via CTGF antisense or anti-CTGF 
antibody have not reported adverse 
effects (Guha et al., 2007; Ponticos 
et al., 2009), and mice carrying a 
single functional CTGF allele exhibit 
no obvious phenotype. Furthermore, 
results of clinical trials using a human 
anti-CTGF monoclonal antibody, 
FG-3019, show that FG-3019 has 
been well tolerated in all studies to 
date. The adult function of CTGF has 
received little attention compared 
with the extensive literature on the 
role and association of CTGF in dis-
ease states involving fibrosis and, 
more recently, cancer (Leask et al., 
2009; Cicha and Goppelt-Struebe, 
2009; Abraham, 2008). To summa-
rize, CTGF expression and protein 
are elevated in nearly all fibrotic tis-
sues examined. Exceptions appear to 
involve inactive disease processes in 
which affected tissue has progressed 
to inert scar tissue. Increased CTGF 
concentrations in blood and other bio-
logical fluids have also been reported 
for many fibrotic diseases. As a result, 
there is active interest in CTGF’s util-
ity as a diagnostic and prognostic bio-
marker (Abraham, 2008; Leask et al., 
2009; Gressner and Gressner, 2009). 
Associations between CTGF and can-
cer are less consistent, with both posi-
tive and negative correlations reported 
(Chu et al., 2008; Cicha and Goppelt-
Struebe, 2009). This variation could 
reflect a context-dependent action of 
CTGF, as described below.
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targeting VEGF. In summary, CTGF as 
a matricellular protein may normally 
integrate and communicate extra-
cellular matrix (ECM)-transmitted 
molecular signals, thereby coordin ating 
cellular function. Besides the possible 
cell- or tissue-specific mech anisms, 
its numerous binding partners provide 
opportunities for context-dependent 
CTGF action because local factor con-
tent and availability, as well as CTGF 
content and form, will contribute to the 
resultant interaction.
In fibrotic disease, dysregulated 
CTGF expression results in abnor-
mally elevated CTGF content that in 
turn could favor aberrant interaction 
dynamics between CTGF and its bind-
ing partners. This situation could create 
an environment where the fibrogenic, 
inflammatory, or angiogenic activity 
of other factors that are usually neu-
tralized or accumulated are instead 
enhanced, promoting inappropriate 
responses or outcomes. Similarities 
could be expected for the opposite 
situation, in which abnormally low 
levels of CTGF could lead to aberrant 
interaction dynamics with its binding 
partners. Hence, if aging is considered 
pathogenic—and our thinking certainly 
comes and goes on this topic—reduced 
CTGF production could be said to cre-
ate an environment that permits inap-
propriate responses.
Data consistent with the idea that 
regulated CTGF levels are important 
for tissue homeostasis were reported in 
a recent publication by Nguyen et al. 
(2008). They found that recombinant 
human CTGF injected intraperitone-
ally in mice was first briefly detected in 
the circulation, followed by evidence 
of reduced BMP7 signaling in the kid-
ney. This outcome was not surprising 
because CTGF–BMP4 interaction has 
been reported to block BMP4 from 
binding to its receptor and triggering 
signaling in lung epithelial cells (Abreu 
et al., 2002), but it confirmed a similar 
relationship for CTGF–BMP7 interac-
tion and, importantly, demonstrated 
that intact biological systems can be 
sensitive to changes in CTGF levels, 
even when these occur in different tis-
sue compartments. This finding also 
emphasizes the need to understand 
details of CTGF metabolism in vivo. 
If suitable models were identified, it 
would be interesting to test whether this 
approach could restore young skin’s 
type I procollagen expression levels to 
aged skin.
In addition to binding partners, 
microenvironment, and metabolism, 
mechanisms that might contribute to 
reduced CTGF expression in aging skin 
include (i) feedback from other CCN gene 
family members and (ii) epi genetic modi-
fication affecting CTGF gene expression. 
Very little is known about the influence 
of the other CCN gene family proteins 
and whether they affect the interactions 
between CTGF and its binding partners 
or alter CTGF gene expression. Quan et 
al. (2010) report that CTGF knockdown 
in normal adult dermal fibroblasts had 
no effect on any of the other five CCN 
gene family mRNA levels, and they 
point out that this indicates that expres-
sion of other CCN family members is not 
dependent on or controlled by CTGF, at 
least not in dermal fibroblasts. However, 
this may not accurately reflect the situa-
tion in vivo. There is evidence for coor-
dinate up- or downregulation of CTGF 
and Cyr61 in primary gliomas (Xie et 
al., 2004) and lung cancers (Chen et 
al., 2007), whereas in animal models of 
renal fibrotic disease, CTGF is elevated 
and Cyr61 is reduced (Sawai et al., 2007; 
Mason, 2009). Epigenetic changes affect-
ing CTGF gene expression may also 
explain reduced CTGF in aging skin. 
There is emerging evidence for this idea, 
especially as it applies to the variability 
of CTGF and cancer associations; this 
topic is a focus of a recent review (Cicha 
and Goppelt-Struebe, 2009). Given 
the link between epigenetic effects and 
aging, it seems rational to explore this 
area further.
ctGF sources, forms, and research tools
Cellular sources of CTGF have been 
determined to include multiple mesen-
chymal and epithelial cell types as well as 
vascular smooth muscle and endothelial 
cells. CTGF appears to be constitutively 
present at low levels in adult tissues 
and biological fluids, and elevated 
expression is thought to be restricted to 
processes involving injury, tissue repair, 
and the generation of connective tissue. 
Tissue content could derive from local 
production or deposition from the circu-
lation. Thus, evaluation of tissue CTGF 
protein is the best way to determine the 
functional importance of CTGF at a par-
ticular site. Currently, the details of CTGF 
trafficking and metabolism that are need-
ed to understand the sources of CTGF 
are lacking.
Quan et al. (2010) report that nor-
mal skin CTGF immunolocalization, 
Figure 2. CTGF domain structure, reported binding partners, and signaling effects. CTGF is a 
multimodular matricellular protein that binds, modulates signaling, and coordinates activities of 
biologically active factors. BMP, bone morphogenetic protein; Cys, cystine; ECM, extracellular matrix; 
HSPG, heparan sulfate proteoglycan; IGF, insulin-like growth factor; LRP, lipoprotein receptor–related 
protein; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor.
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primarily to vascular and interstitial 
cells, is consistent with expectations; 
however, the authors point out that 
localization appears to be intracellular, 
possibly because the detecting antibody 
recognized the CTGF C-terminal half. 
As expected for a matricellular pro-
tein, newly synthesized CTGF has been 
reported to be quantitatively secreted 
in cell culture (Chen et al., 2001), so a 
lack of extracellular staining in skin is 
surprising. Secreted CTGF is likely to be 
complexed with macromolecular bind-
ing partners, including proteoglycans 
and glycosaminoglycans in the ECM. 
Therefore, extracellular CTGF detec-
tion may require “unmasking” of CTGF 
epitopes. Alternatively, because CTGF 
is readily cleaved at the central hinge 
to N- and C-terminal half fragments 
and the C-terminal half fragment is 
internalized (Chen et al., 2001), ECM-
sequestered CTGF might not be the 
full-length molecule and therefore may 
not be recognized by the detecting anti-
body used by Quan et al. Quan et al. 
report that dermal fibroblasts expressed 
primarily 38- and 35-kDa forms of 
CTGF, but that other small CTGF frag-
ments were also detected, indicating 
that the major cellular source in skin is 
capable of CTGF fragment generation. 
Thus, immunohisto chemical evaluation 
using a C-terminal reactive antibody to 
detect CTGF is likely to represent main-
ly newly synthesized or endocytosed 
CTGF and, potentially, an incomplete 
picture of abundance and localization 
in the skin.
Although context-dependent action 
of CTGF could explain discrepant find-
ings in the literature on CTGF activity 
and functional significance, more triv-
ial, but important, explanations should 
also be considered—specifically, 
reagent suitability and properties. Two 
recent publications reporting the effects 
of CTGF on inflammation illustrate the 
importance of using comparable CTGF 
materials. One study reports that CTGF 
has no effect on inflammation (Ponticos 
et al., 2009); the other paper shows that 
CTGF stimulates NF-κB signaling, con-
sistent with CTGF’s promoting inflam-
mation (Sanchez-Lopez et al. 2009). 
The CTGFs used in these studies differ 
significantly: one is a flag-tagged, mam-
malian cell–derived full-length human 
CTGF and the other is an Escherichia 
coli–derived human CTGF domain 4 
(11.2 kDa). The discrepant findings on 
CTGF’s role in inflammation could rep-
resent context-dependent differences 
in the experimental systems used, but 
reagent differences deserve consid-
eration as well. It is possible that this 
activity is fragment specific, a situa-
tion for which there is much biological 
precedent (e.g., endostatin). Indeed, an 
obvious complicating outcome is the 
confusion that can result when some 
investigators use fragments and others 
use full-length CTGF.
concluding remarks
The results reported by Quan et al. 
(2010) provide new insight into skin 
aging and identify CTGF as a key play-
er for the decline in collagen content. 
The findings confirm the complexity of 
mechanisms whereby CTGF and TGF-β 
collaborate and act independently and 
raise new questions regarding these 
pathways and how they are affected 
by aging. Although opposite effects on 
regulation of the TGF-β/CTGF/collagen 
axis in aging and fibrosis are not surpris-
ing, the contrast offers an opportunity 
to define the underlying mechanisms. 
Identifying the overlapping and unique 
components that drive these oppos-
ing processes could provide insight for 
reinstating balance and thus strategies 
to control or reverse fibrosis, as well 
as to improve properties of aging skin. 
Undoubtedly, the research on CTGF’s 
physiological significance will build 
on the results reported by Quan et al., 
with the potential for beneficial appli-
cations of CTGF and its regulatory pro-
gram. In addition to improving aging 
skin, the results might have implica-
tions for some disorders of fragile skin 
(or bone) and impaired wound healing; 
or, perhaps one should even consider 
what CTGF might do for wrinkles.
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